Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,1106€
Last updated
09/10/2025 - 09:10
+21,54%
€7.6m
Total sales in 2024
+40
Commercial opportunities following CellTolerance launch
+48%
PPU growth in 2024 vs.
2022
excluding exchange rates
Events and Presentations
Financial Results
Governance
MKT – Webinar – October 6, 2025 (French only)
No results found.
Voting Rights Information – September 2025
No results found.
2025 Half-Year Financial Report (free translation)
No results found.
Corporate Presentation September 2025
No results found.
Voting Rights Information – August 2025
No results found.
News
Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan
Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring
Mauna Kea Technologies Announces 2025 Half-Year Results
No results found.
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 79,439,997
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
GILBERT DUPONT
Guillaume Cuvillier
EUROLAND CORPORATE
EUROLAND CORPORATE
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France